In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective
- 23 April 2009
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 37 (7), 1339-1354
- https://doi.org/10.1124/dmd.109.027029
Abstract
Cytochrome P450 (P450) induction is one of the factors that can affect the pharmacokinetics of a drug molecule upon multiple dosing, and it can result in pharmacokinetic drug-drug interactions with coadministered drugs causing potential therapeutic failures. In recent years, various in vitro assays have been developed and used routinely to assess the potential for drug-drug interactions due to P450 induction. There is a desire from the pharmaceutical industry and regulatory agencies to harmonize assay methodologies, data interpretation, and the design of clinical drug-drug interaction studies. In this article, a team of 10 scientists from nine Pharmaceutical Research and Manufacturers of America (PhRMA) member companies conducted an anonymous survey among PhRMA companies to query current practices with regards to the conduct of in vitro induction assays, data interpretation, and clinical induction study practices. The results of the survey are presented in this article, along with reviews of current methodologies of in vitro assays and in vivo studies, including modeling efforts in this area. A consensus recommendation regarding common practices for the conduct of P450 induction studies is included.Keywords
This publication has 106 references indexed in Scilit:
- Time course of the increase in 4β‐hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsyBritish Journal of Clinical Pharmacology, 2008
- Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding SitesMolecular Pharmacology, 2007
- Induction of drug metabolizing enzymes: A survey of in vitro methodologies and interpretations used in the pharmaceutical industry—Do they comply with FDA recommendations?Chemico-Biological Interactions, 2007
- Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and inductionExpert Opinion on Drug Metabolism & Toxicology, 2006
- Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activityBritish Journal of Clinical Pharmacology, 2006
- Infection of a human hepatoma cell line by hepatitis B virusProceedings of the National Academy of Sciences of the United States of America, 2002
- Expression and Induction of CYP2C P450 Enzymes in Primary Cultures of Human HepatocytesThe Journal of pharmacology and experimental therapeutics, 2002
- Recent Advances in Human Hepatocyte Culture SystemsBiochemical and Biophysical Research Communications, 2000
- RitonavirClinical Pharmacokinetics, 1998
- Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptorBiochemical and Biophysical Research Communications, 1992